ReShape Lifesciences Inc.

NASDAQ: RSLS · Real-Time Price · USD
3.92
0.72 (22.50%)
At close: Aug 14, 2025, 3:59 PM

ReShape Lifesciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
8.01M 8.68M 11.24M 13.6M
Cost of Revenue
2.95M 3.13M 4.44M 5.25M
Gross Profit
5.06M 5.55M 6.8M 8.35M
Operating Income
-6.67M -14.64M -27.08M -27.75M
Interest Income
14K 26K n/a n/a
Pretax Income
-7.09M -11.34M -46.59M -62.04M
Net Income
-7.13M -11.39M -46.21M -61.93M
Selling & General & Admin
9.92M 17.87M 31.34M 33.58M
Research & Development
1.8M 2.31M 2.54M 2.52M
Other Expenses
n/a n/a 11K n/a
Operating Expenses
11.72M 20.19M 33.88M 36.1M
Interest Expense
n/a n/a 113K 832K
Selling & Marketing Expenses
2.99M 7.55M 14.09M 9.16M
Cost & Expenses
14.67M 23.32M 38.32M 41.35M
Income Tax Expense
39K 52K -380K -106K
Shares Outstanding (Basic)
515.57K 102.7K 7.32K 3.77K
Shares Outstanding (Diluted)
515.57K 102.7K 7.32K 3.77K
EPS (Basic)
-13.83 -110.88 -6.32K -16.44K
EPS (Diluted)
-13.83 -110.88 -6.32K -16.44K
EBITDA
-6.67M -14.48M -24.93M -60.62M
EBIT
-6.67M -14.64M -27.08M -62.59M
Depreciation & Amortization
n/a 154K 2.15M 1.97M